Pouryousefi Elahe, Javadi Maryam, Hashemipour Sima, Nooshabadi Mohamadreza Rashidi, Haghighian Hossein Khadem
Department of Nutrition, School of Health, Qazvin University of Medical Sciences, Qazvin, Iran.
Children Growth Research Center, Research Institute for Prevention of Non-Communicable Diseases, Qazvin University of Medical Sciences, Qazvin, Iran.
Diabetol Metab Syndr. 2022 Jun 3;14(1):77. doi: 10.1186/s13098-022-00848-3.
The anti-inflammatory properties of cannabinoids have been shown. This study was conducted to assess effect of oleoylethanolamide (OEA) supplementation on glycemic status, insulin resistance (IR) and inflammatory factor in pre-diabetic individuals.
This double-blind randomized clinical trial was done at Qazvin University of Medical Sciences in which 46 pre-diabetic patients were divided into two equal groups and received one 125 mg OEA capsule in the intervention group (23 subjects) and 125 mg capsule containing wheat flour in placebo group daily for 8 weeks. After collecting demographic information, at the beginning and end of the study, the questionnaires of physical activity, 24-hour food recall were completed and blood glucose (BG), plasma insulin level, IR, hemoglobin Ac (HbAc), and C-reactive protein (CRP) were measured. Statistical analysis was performed using SPSS software.
At the beginning and end of the study, there was no significant difference between the two groups in terms of anthropometric indices, food intake and physical activity (P > 0.05). At the end of the study, consumption of OEA significantly reduced BS, insulin, IR, HbAc, and CRP (P < 0.05). No significant change was observed in mentioned biochemical factors in placebo group (P > 0.05).
Given that OEA supplementation improved the glycemic status, IR and reduced the inflammatory factor, use of this supplement can be introduced as a useful supplement to control pre-diabetes status.
The protocol of this clinical trial is registered with the Iranian Registry of Clinical Trials ( http://www.IRCT.IR , identifier: IRCT20141025019669N16).
大麻素的抗炎特性已得到证实。本研究旨在评估补充油酰乙醇胺（OEA）对糖尿病前期个体血糖状态、胰岛素抵抗（IR）和炎症因子的影响。
这项双盲随机临床试验在加兹温医科大学进行，46名糖尿病前期患者被分为两组，干预组（23名受试者）每天服用一粒125毫克的OEA胶囊，安慰剂组每天服用一粒含小麦粉的125毫克胶囊，持续8周。在收集人口统计学信息后，于研究开始和结束时，完成身体活动问卷、24小时食物回顾，并测量血糖（BG）、血浆胰岛素水平、IR、糖化血红蛋白（HbAc）和C反应蛋白（CRP）。使用SPSS软件进行统计分析。
在研究开始和结束时，两组在人体测量指标、食物摄入量和身体活动方面无显著差异（P>0.05）。研究结束时，服用OEA显著降低了血糖、胰岛素、IR、HbAc和CRP（P<0.05）。安慰剂组上述生化因素未观察到显著变化（P>0.05）。
鉴于补充OEA改善了血糖状态、IR并降低了炎症因子，可将这种补充剂作为控制糖尿病前期状态的有用补充剂。
本临床试验方案已在伊朗临床试验注册中心注册（http://www.IRCT.IR，标识符：IRCT20141025019669N16）。
